Date Mailed: July 272000

FORM 1449*

INFORMATION DISCLOSURE STATEMENT 3 1 2000

IN AN APPLICATION

(Use several sheets if necessary)

Sheet 1 of 3

Docket Number: 11998.20US01

Application Number: 09/591,754

Applicant: WALSH ET AL.

Filing Date: 06/12/2000

Group Art Unit: UNKNOWN

_			U.S. PATENT DOCUMEN	rs		
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
26	3,983,863	10/05/1976	Janke et al.			
	4,048,990	09/20/1977	Goetz			
7	4,428,375	01/31/1984	Ellman			
	4,630,597	12/23/1986	Kantrowitz et al.			
	4,690,134	09/01/1987	Snyders			
1	4,821,723	04/18/1989	Baker, Jr. et al.			
	4,878,890	11/07/1989	Bilweis			
	4,936,857	06/26/1990	Kulik			
1	4,957,477	09/18/1990	Lundbäck			
	4,973,300	11/27/1990	Wright			•
	4,976,730	12/11/1990	Kwan-Gett			
1	5,057,117	10/15/1991	Atweh			
	5,087,243	02/11/1992	Avitall			
	5,131,905	07/21/1992	Grooters			
	5,150,706	09/29/1992	Cox et al.			
	5,186,711	02/16/1993	Epstein			
	5,192,314	03/09/1993	Daskalakis	-		
	5,256,132	10/26/1993	Snyders			
	5,290,217	03/01/1994	Campos			
	5,356,432	10/18/1994	Rutkow et al.			
1	5,383,840	01/24/1995	Heilman et al.			
	5,385,156	01/31/1995	Oliva			
1	5,429,584	07/04/1995	Chiu			
	5,507,779	04/16/1996	Altman			
	5,524,633	06/11/1996	Heaven et al.			
	5,603,337	02/18/1997	Jarvik			-
	5,647,380	07/15/1997	Campbell et al.			
·V	5,702,343	12/30/1997	Alferness			
$\overline{\vee}$	5,713,954	02/03/1998	Rosenberg et al.			
126	5,800,528	09/01/1998	Lederman et al.			

EXAMINER	KOZI	INVA	MAMORE

DATE CONSIDERED

4/22/02

Date Mailed: July 27, 2000

Sheet 2 of 3

FO	RM	144	9

INFORMATION DISCLOSURE STATEMENT

JUL; 3 1 2000

Docket Number: 11998.20US01

Application Number: 09/591,754

IN AN APPLICATION

(Use several sheets if necessary)

Applicant: WALSH ET AL.

Filing Date: 06/12/2000

Group Art Unit: UNKNOWN

RO	5,961,440		10/05/1999	Schweich, Jr. et al.					
]	5,990,378		11/23/1999	Ellis					
	6,045,497		04/04/2000	Schweich, Jr. et al.			<u> </u>		
W	6,050,936		04/18/2000	Schweich, Jr. et al.					
RO	6,059,715		05/09/2000	Schweich, Jr. et al.					
			F	OREIGN PATENT DOCUME	NTS	<u> </u>			
	DOCUMENT NO.		DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
							YES	NO	
K6	295 17 393 U	J1,	03/14/1996	DE			х		
16	0 280 564 A	2 -	08/31/1988	EP					
,. 	-60-20 3250 A	2-3	_10/.14/.19.85	JP				х	
26	01-145066 A	. •	06/07/1989	JР			Abstract		
1	WO 98/2904	1 .	07/09/1998	PCT					
	WO 98/5859	8 .2	12/30/1998	PCT			х		
	WO 99/4453	4 .	09/10/1999	PCT					
	WO 00/0602		02/10/2000	PCT					
	WO 00/0602	7 .	02/10/2000	PCT					
y	WO 00/0602	8 .	02/10/2000	PCT					
	WO 00/1670	0.	03/30/2000	PCT					
Kb	1009457 A	1	04/07/1983	su					
-		ОТ	HER DOCUMEN	TS (Including Author, Title, Da	ate, Pertinent Pages	s, Etc.)			
Rlo		"Supplemen	t to Circulation", A	bstracts from the 68th Scientific	c Sessions, Vol. 92	, No. 8, 2 pages (Oct	ober 15, 1995).		
	:	 Capomolla, S. et al., "Dobutamine and nitroprusside infusion in patients with severe congestive heart failure: Hemodyna improvement by discordant effects on mitral regurgitation, left atrial function, and ventricular function", American Heart pp. 1089-1098 (December 1997). Capouya, E. et al., "Girdling Effect of Nonstimulated Cardiomyoplasty on Left Ventricular Function", Ann Thorac. Surg. pp. 867-871 (1993). Cohn, J., "The Management of Chronic Heart Failure", The New England Journal of Medicine, Vol. 335, No. 7, pp. 490-4 (August 15, 1996). Coletta, C. et al., "Prognostic value of left ventricular volume response during dobutamine stress echocardiography:, Eur Journal, Vol. 18, pp. 1599-1605 (October 1997). 							
							, Ann Thorac. Si	arg., Vol. 56,	
							35, No. 7, pp. 49	, pp. 490-498	
							cardiography:, I	European He	
		Guasp, F., "I pp. 521-528	Una prótesis conte (July 1998).	ntiva para el tratamiento de la m	iocardiopatía dilata	ada", Revista Españo	ola de Cardiolog	ría, Vol 51, N	
V		Kass, D. et a	I., "Reverse Remo	deling From Cardiomyoplasty ir	n Human Heart Fail	ure External Constr	aint Versus Act	ve Assist",	

۸.	. 1		
EXAMINER KD2 (MAKOUNAN	DATE CONSIDERED U 221	OL
		0. 0	

Date Mailed: July 2000

JUL 3 1 2000



Sheet 3 of 3

FORM 1449*

INFORMATION DISCLOSURE STATEMENT

IN AN APPLICATION

(Use several sheets if necessary)

 Docket Number:
 Application Number:

 11998.20US01
 09/591,754

Applicant: WALSH ET AL.

Filing Date: 06/12/2000 Group Art Unit: UNKNOWN

. 26	Levin, H. et al., "Reversal of Chronic Ventricular Dilation in Patient With End-Stage Cardiomyopathy by Prolonged Mechanical Unloading", Circulation, Vol. 91, No. 11, pp. 2717-2720 (June 1, 1995).
	Oh, J. et al., "The Effects Of Prosthetic Cardiac Binding and Adynamic Cardiomyoplasty In A Model Of Dilated Cardiomyopathy", <i>The Journal of Thoracic and Cardiovascular Surgery</i> , Vol. 116, No. 1, pp. 148-153 (July 1998)
. 💖	Paling, D., "Warp Knitting Technology", Columbine Press, pg. 111 (1965).
. Kb	Vaynblat, M. et al., "Cardiac Binding in Experimental Heart Failure", Ann. Thorac. Surg., Vol. 64, 11 pages, (1997).

23552
PATENT TRADEMARK OFFICE

EXAMINER ROZ Charonan

DATE CONSIDERED

4/72/01)

Sheet I of I

Date Mailed: July 2.2	2001
FORM PRICE CONFOR	RMATION DISCLOSURE STATE
mi 0 9 2001	IN AN APPLICATION

EMENT

(Use several sheets if necessary)

Docket Number:	Application Numb
11998.20US01	09/591,754

Applicant: WALSH ET AL.

Filing Date: 06/12/2000 Group Art Unit: 3739

_		U	.S. PATENT DOCUMENT	rs			_	
EXAMINER INITIAL	DOCUMENT NO.	DOCUMENT NO. DATE		CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
		FOR	EIGN PATENT DOCUMI	ENTS				
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
						YES	NO	
			 					
	ОТН	ER DOCUMENTS	S (Including Author, Title, D	ate, Pertinent Page	s, Etc.)		<u> </u>	
RG		Avitall, B. et al., "Iontophoretic Transmyocardial Drug Delivery A Novel Approach to Antiarrhythmic Drug Therapy", Circulation, Vol. 85, No. 4, pp. 1582-1593 (April 1992)						
	Kessler, P.D. et al., "Myoblast Cell Grafting into Heart Muscle: Cellular Biology and Potential Applications", Annu. Physiol., Vol. 61, pp. 219-242 (1999)						и. Rev.	
		Labhasetwar, V. et al., "Sotalol Controlled-Release Systems for Arrhythmias: In Vitro Characterization, in Vivo Drug Disposition, and Electrophysiologic Effects", <i>Journal of Pharmaceutical Sciences</i> , Vol. 83, No. 2, pp. 156-164 (February						
		Labhasetwar, V. et al., "Epicardial Administration of Ibutilide from Polyurethane Matrices: Effects on Defibrillation Thres and Electrophysiologic Parameters", J. Cardiovasc. Pharmacol., Vol. 24, No. 5, pp. 826-840 (1994)						
	Labhasetwa pp. 2612-26	, V. et al., "Iontoph 16 (March 1995)	noresis for Modulation of Ca	rdiac Drug Deliver	y in Dogs", <i>Proc. Na</i>	ıtl. Acad. Sci. U	<i>ISA</i> , Vol. 92	
	Labhasetwa Journal of P	, V. et al., "A DNA harmaceutical Scie	Controlled-Release Coating	g for Gene Transfe 347-1350 (Novemb	r: Transfection in Sk per 1998)	eletal and Card	liac Muscle"	
	Labhasetwa Electrode", .	, V. et al., "Preven J. Cardiovasc. Pha	tion of Acute Inducible Atria	al Flutter in Dogs b 149-455 (1998)	y Using an Ibutilide-	Polymer-Coate	d Pacing	
	Li, R. et al.,	"Cell Therapy to R	epair Broken Hearts", Can.	J. Cardiol., Vol. 14	l, No. 5, pp. 735-744	(May 1998)	5.5.5	
	Mond, H. et	al., "The Steroid-E	luting Electrode: A 10-Year	Experience", PAC	CE, Vol. 19, pp. 1016	-1020 (July 199	96)	
			ntrolled-Release Verapamil I Cardiovasc. Pharmacol., V			des Induced by	Acute	
1,			panolol Administration for V c, Vol. 13, No. 11, pp. 764-7		ımias in Dogs: Matri	x Formulation	and	
~			picardial Controlled-Release Cardiovasc. Pharmacol., V			Induced by Ra	pid	

PATENT TRADEMARK OFFICE

EXAMINER

DATE CONSIDERED

1